Del-desiran Misses Phase III HARBOR Primary Endpoint
Novartis disclosed that Phase III HARBOR did not show a statistically significant improvement versus placebo on video hand opening time, the primary endpoint in myotonic dystrophy type 1. The company reported evidence of activity…
